Medical Policy Gene-Based Tests for Screening, Detection, and/or Management of Prostate Cancer

Policy Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO Blue and Medicare PPO Blue Members Genetic tests for the screening, detection, and management of prostate cancer are INVESTIGATIONAL. This includes, but is not limited to the following:  Single-nucleotide polymorphisms (SNPs) for risk assessment, or  PCA3 for disease diagnosis and prognosis, or  TMPRSS fusion genes for diagnosis and prognosis, or  Multiple gene tests (gene panels) for prostate cancer diagnosis, or  Gene hypermethylation for diagnosis and prognosis.